SANTA CLARA, Calif. & BOSTON--(BUSINESS WIRE)--Sept. 7, 2006--Affymetrix Inc. (Nasdaq:AFFX) and Partners HealthCare announced today that they have entered into a three-year translational research collaboration to develop microarray-based diagnostics for complex diseases such as newborn hearing loss, autism and hypertrophic cardiomyopathy. Under the terms of the agreement, Partners researchers at Harvard Medical School (HMS), Partners HealthCare and Harvard Medical School-Partners HealthCare Center for Genetics and Genomics (HPCGG) will create and validate microarray tests in Clinical Laboratory Improvement Amendments (CLIA) laboratories.
